Conclusions
The efficacy and safety results in the Japanese subgroup were consistent with the overall population of CheckMate 274.Adjuvant nivolumab improved disease-free survival in Japanese patients, with no impairment in quality of life and a safety profile consistent with that of the overall study population of CheckMate 274.